Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.41 |
| ▸ | ACACB | O00763 | 5/20 | 0.41 |
| ▸ | GPR6 | P46095 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 4/20 | 0.37 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12099455 | 0.85 | KCNH2 (0.45) | MAPK14CHRM4ACACBGPR6KCNH2 | |
| SCHEMBL12100080 | 0.83 | ACACB (0.45) | MAPK14CHRM4ACACBFFAR1FPR2 | |
| SCHEMBL12099754 | 0.83 | P2RX3 (0.40) | MAPK14CHRM4ACACBGPR6KCNH2 | |
| SCHEMBL12099601 | 0.77 | MAPK14 (0.48) | MAPK14CHRM4ACACBGPR6KCNH2 | |
| SCHEMBL12099593 | 0.77 | ALDH1A1 (0.45) | MAPK14CHRM4GPR6KCNH2HRH3 | |
| SCHEMBL12100128 | 0.76 | MAPK14 (0.43) | MAPK14CHRM4ACACBKCNH2HRH3 | |
| SCHEMBL12099405 | 0.75 | MAPK14 (0.48) | MAPK14CHRM4GPR6KCNH2HRH3 | |
| SCHEMBL12100236 | 0.74 | ACACB (0.41) | ACACBKCNH2HRH3PDE3BPDE3A | |
| SCHEMBL12100285 | 0.73 | MAPK14 (0.44) | MAPK14CHRM4ACACBGPR6KCNH2 | |
| SCHEMBL12099552 | 0.73 | ACACB (0.49) | MAPK14ACACBFFAR1FPR2PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | MAPK14 4019/4885CHRM4 1127/4885ACACB 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.